Moderna Spikevax COVID-19 vaccine

All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality.

Name: Moderna Spikevax® COVID-19 vaccine

Manufacturer: ModernaTX, Inc.

Type: mRNA

Status: Approved by Health Canada

Approved for: Age 6 and older

How it's given: Injection in muscle (usually the upper arm)

Number of doses: 2 doses

On this page

Who the vaccine is approved for

The vaccine is approved for people who are 6 years of age and older. Its safety and effectiveness in people younger than 6 years of age have not yet been established.


Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax® COVID vaccine was:


The dosing schedule approved by Health Canada is to give 2 doses (100 micrograms each for ages 12 and older or 50 micrograms each for ages 6 to 11) 1 month apart, based on evidence from clinical trials.

A booster dose (50 micrograms) of the Moderna Spikevax® COVID-19 vaccine may be administered in individuals 18 years of age and older at least 6 months after completing their primary vaccine series.

Dose volume depends on which series of the vaccine is being administered. The dose for individuals 12 years of age and older (100 micrograms) is twice the dose used for children 6 to 11 years of age (50 micrograms). The booster dose is also 50 micrograms.

Check the colour of the vial cap and the corresponding dose volumes to select the appropriate dose volume for the vaccine series being administered. The 0.2 mg/mL multi-dose vial has a red plastic cap. The 0.1 mg/mL multi-dose vial has a royal blue plastic cap. The vials with royal blue caps make it easier to administer smaller doses.

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence.

Learn more about:

Mixed dose schedules

A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty® as your first dose and be offered Moderna Spikevax® as your second. This is known as a mixed vaccine series.

The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty® or Moderna Spikevax®) should be offered for your second dose.

Learn more about:

Vaccine ingredients

Medicinal ingredient

Other ingredients

This vaccine does not contain any:

Possible side effects

After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination.

This is the body's natural response, as it's working hard to build protection against the disease.

Common vaccine side effects may include:

Symptoms at the injection site, such as: More general symptoms, such as:
  • redness
  • soreness
  • swelling
  • chills
  • fatigue
  • joint pain
  • headache
  • mild fever
  • muscle aches
  • nausea
  • vomiting

Rare vaccine side effects

Rare reactions that have been reported and confirmed after taking an mRNA vaccine are:

A severe allergic (anaphylaxis) reaction is also rare. Signs and symptoms of anaphylaxis may include:

Call emergency services if you develop or witness any serious symptoms that could be an allergic reaction after vaccination.

Reporting a possible serious reaction

Contact your health care provider if you experience:

Health care providers must report possible reactions following vaccination to their local public health authority. The public health authority then reports them to the Public Health Agency of Canada.

Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report.

Vaccine review, approval and monitoring

Health Canada's independent drug review process is recognized around the world for its high standards and rigor. Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. The benefits must also outweigh any risks.

The Moderna COVID-19 vaccine was authorized for use in Canada under the Interim Order respecting the importation, sale and advertising of drugs for use in relation to COVID-19. The interim order expired on September 16, 2021. On this date, Moderna Spikevax® transitioned to an authorization under the Food and Drug Regulations.

Find detailed technical information such as the product monograph and the regulatory decision summary:

As COVID-19 vaccines are administered across Canada, our safety monitoring is ongoing. The Public Health Agency of Canada, Health Canada, and provincial and territorial health authorities continue to:

Learn about the side effects we're currently monitoring.

Get vaccinated

How to get vaccinated near you

Related links

Did you find what you were looking for?

What was wrong?

You will not receive a reply. Telephone numbers and email addresses will be removed.
Maximum 300 characters

Thank you for your feedback

Date modified: